Skip to main content

Table 1 Characteristics of ESPOIR RA patients at inclusion

From: Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients

 ESPOIR cohort
All RA patients (n = 487)HCMV seropositive RA patients (n = 273) (56%)HCMV seronegative RA patients (n = 214) (44%)p (HCMV+ versus HCMV−)
Baseline characteristics (inclusion)
 Age, years, median (IQR)***50.3 (40.0–57.1)52.9 (43.1–58.5)***47.8 (37.4–54.3)0.0001
 Gender, female, n (%)378 (77.6)219 (80.2)159 (74.3)0.1197
 Symptom duration, year, median (IQR)0.42 (0.26–0.64)0.41 (0.25–0.62)0.42 (0.27–0.65)0.5108
 ACPA+, n (%)*262 (53.8)136 (49.8)*126 (58.9)0.0465
 RF+, n (%)296 (60.8)163 (59.7)133 (62.1)0.5837
 Disease Activity Score 28 (DAS28-ESR), mean (IQR)*5.40 (± 1.21)5.55 (± 1.24)*5.20 (± 1.14)0.0013
 Erythrocyte sedimentation rate (ESR), median (IQR)24 (12–39)24 (14–46)22.5 (10.5–35.5)0.0566
 C-reactive protein (CRP), median (IQR)10 (3–24)9 (3–24)11 (3–24)0.5510
 Total Sharp score (TSS), median (IQR)4 (1–8)4 (1–8)3 (1–8)0.6745
 Erosion Sharp score (ESS), median (IQR)1 (0–4)1 (0–4)1 (0–4)0.5420
 Joint space narrowing Sharp score (NSS), median (IQR)1 (0–4)1 (0–4)1 (0–4)0.9121
  1. * p < 0.05; *** p < 0.001
\